The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients with Cystic Fibrosis

The content for this activity is based on the live, inter professional seminar titled, “The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis” that was presented at the 31st Annual North American Cystic Fibrosis Conference in Indianapolis, Indiana. This CME/CNE activity will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with cystic fibrosis.

LEARNING OUTCOME STATEMENTS

At the conclusion of this activity:

KNOWLEDGE: Participants will self-report knowledge gained based on current best practices for improving outcomes and quality of life in patients with cystic fibrosis.

COMPETENCE/SKILL: Participants will self-report intent to change practice by applying current best practices for improving outcomes and quality of life in patients with cystic fibrosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to do the following:

  1. Review pathophysiology, genomic evaluation and functional implications of CF, including the underlying causing of disease to guide therapeutic selection
  2. Examine clinical trial data of emerging combination therapies for the treatment of CF
  3. Implement a data-driven and personalized CFTR modulated treatment plan to improve the life-long management of patients with CF

FACULTY

John P. Clancy, MD (Chair)
Professor of Pediatrics
Director, Pulmonary Medicine Research
Co- Director, CF Research Development Program
Medical Director, Office of Clinical and Translational Research
Gunnar Esiason/Cincinnati Bell Chair in Life Sciences Research
Division of Pulmonary Medicine
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Jane Davies, MD
Professor of Paediatric Respirology and Experimental Medicine
Imperial College London
Honorary Consultant in Paediatric Respiratory Medicine
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom
Carlos Milla, MD
Professor and Director
The Stanford Cystic Fibrosis Center
Associate Director for Translational Research
Center for Excellence in Pulmonary Biology
Stanford University
Palo Alto, California
Kristin A. Riekert, PhD
Associate Professor
Director, Johns Hopkins Adherence Research Center
Director, Cystic Fibrosis Adherence Program
Johns Hopkins School of Medicine
Baltimore, Maryland
Gregory Sawicki, MD, MPH
Director, Cystic Fibrosis Center
Boston Children's Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts
Jennifer L. Taylor-Cousar, MD, MSCS
Medical Director, Clinical Research Services
Co-Director and CF TDN Director, Adult CF Program
Associate Professor, Departments of Medicine and Pediatrics
Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine
Denver, Colorado

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
John P. Clancy, MD
Consultant/Advisor: Gilead
Grant/Research Support: Bayer AG, Concert Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, ProQR Therapeutics
Speaker's Bureau: Genentech, Inc.

Jane Davies, MD

Consultant/Advisor: AbbVie Inc.; AlgiPharma; Enterprise Therapeutics Ltd; Galapagos NV; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated
Carlos Milla, MD
Consultant/Advisor: AbbVie Inc.; Gilead; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Parion Sciences; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated
Kristin A. Riekert, PhD
Consultant/Advisor: Genentech, Inc.
Gregory Sawicki, MD, MPH
Consultant/Advisor: Vertex Pharmaceuticals Incorporated
Jennifer L. Taylor-Cousar, MD, MSCS
Consultant/Advisor: Gilead; Proteostasis Therapeutics, Inc.; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Bayer AG; Celtaxsys; N30 Pharmaceuticals; Vertex Pharmaceuticals Incorporated
Speakers Bureau: Vertex Pharmaceuticals Incorporated
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Marilu Kelly, MSN, RN, CNE; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.

PROVIDER INFORMATION

Provided in collaboration with the Elsevier Office of Continuing Medical Education, Elsevier and AcademicCME.

CME CREDIT (PHYSICIANS)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE CREDIT (NURSES)

Elsevier will award 1.5 contact hours for this activity. No partial credit will be given. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and AcademicCME. EOCME is accredited by the ACCME to provide continuing medical education for physicians.

CME/CNE INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
For all CNE inquiries or special needs, please contact p.harvey@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, AcademicCME and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.  

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician
Course opens: 
12/18/2017
Course expires: 
12/17/2018
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit(s)™
  • 1.50 Nursing Contact Hours
  • 1.50 Non-physician

Accreditation Period

Course opens: 
12/18/2017
Course expires: 
12/17/2018
Please login or register to take this course.